Compound danshen dripping pills for diabetic retinopathy in patients with type 2 diabetes: A superiority, randomized controlled trial

Table 8 Subgroup results of safety³

	CDDP			Placebo			P value
	Cases	n	%2	Cases	n	%2
Adverse event1	143	92	25.41	65	36	29.75	0.344
< 60 (year)	70	49	25.93	36	23	34.33	0.207
≥ 60 (year)	73	43	24.86	29	13	24.07	1.000
Serious adverse events	6	6	1.66	1	1	0.83	0.686
< 60 (year)	3	3	1.59	1	1	1.49	1.000
≥ 60 (year)	3	3	1.73	0	0	0.00	1.000
Withdrawn due to adverse events	7	7	1.93	2	1	0.83	0.686
< 60 (year)	4	4	2.12	2	1	1.49	1.000
≥ 60 (year)	3	3	1.73	0	0	0.00	1.000

¹Adverse reactions refer to three types of reactions that are positively related, possibly related, or undetermined to the investigational drug.

²Percentage = number of safety incidents occurring in each group and layer/total number of subjects in each group and layer.

³The total number of safety set participants in the experimental group was 362 (189 for those under 60 years old and 173 for those over 60 years old); The total number of safety set participants in the control group was 121 (67 for those under 60 years old and 54 for those over 60 years old).

CDDP: Compound danshen dripping pill.